High penetration prodrug compositions of mustards and mustard-related compounds
The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of mustards and mustard-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
1. A compound chosen from:
N,N-diethylaminoethyl 4-[bis(2-chloroethyl)amino]benzenebutyrate.HA; and
diethylaminoethyl 4-[bis(2-methylsulfonylethyl)amino]benzenebutyrate.HA,
wherein HA is selected from hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfic acid, bisulfic acid, phosphoric acid, phosphorous acid, phosphonic acid, isonicotinic acid, acetic acid, lactic acid, salicylic acid, citric acid, tartaric acid, pantothenic acid, bitartaric acid, ascorbic acid, succinic acid, maleic acid, gentisinic acid, fumaric acid, gluconic acid, glucaronic acid, saccharic acid, formic acid, benzoic acid, glutamic acid, methanesulfonic acid, ethanesulfonic acid, benzensulfonic acid, p-toluenesulfonic acid and pamoic acid.
2. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
3. The pharmaceutical composition according to claim 2 , wherein the pharmaceutically acceptable carrier is polar.
4. The pharmaceutical composition according to claim 2 , wherein the pharmaceutically acceptable carrier is chosen from alcohol, acetone, ester, water, and aqueous solution.
5. The compound according to claim 1 , wherein the compound is chosen from N,N-diethylaminoethyl 4-[bis(2-chloroethyl)amino]benzenebutyrate.HBr and diethylaminoethyl 4-[bis(2-methylsulfonylethyl)amino]benzenebutyrate.HBr.